Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3′-deoxy-3′-[18F]fluorothymidine flare

Biochemical Pharmacology

Volumn 80, Issue 10, 2010, Pages 1528-1536

  Lee, Seung Jin ^a   Kim, Seog Young ^a,b   Chung, Jin Hwa ^b   Oh, Seung Jun ^a,b   Ryu, Jin Sook ^a,b   Hong, Yong Sang ^b   Kim, Tae Won ^a,b   Moon, Dae Hyuk ^a,b  

^a Asan Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

5 Fluorouracil; 18F fluorothymidine; Positron emission tomography; Thymidine kinase 1; Thymidylate synthase

Indexed keywords

3' FLUOROTHYMIDINE F 18; CYCLIN A; CYCLOHEXIMIDE; FLUOROURACIL; THYMIDINE KINASE 1; THYMIDYLATE SYNTHASE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; ANTINEOPLASTIC ANTIMETABOLITE; FLUORINE; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; DRUG MECHANISM; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CANCER TRANSPLANTATION; CULTURE TECHNIQUE; ENZYME INDUCTION; ENZYMOLOGY; FLOW CYTOMETRY; GENETICS; IMMUNOBLOTTING; MALE; METABOLISM; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DIDEOXYNUCLEOSIDES; ENZYME INDUCTION; FLOW CYTOMETRY; FLUORINE RADIOISOTOPES; FLUOROURACIL; HUMANS; IMMUNOBLOTTING; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; POSITRON-EMISSION TOMOGRAPHY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYMIDINE KINASE; THYMIDYLATE SYNTHASE;

EID: 77957020004     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.08.004     Document Type: Article

References (35)

1. Longley D.B., Harkin D.P., Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338.
2. Walko C.M., Lindley C. Capecitabine: a review. Clin Ther 2005, 27:23-44.
3. Jackman A.L., Theti D.S., Gibbs D.D. Antifolates targeted specifically to the folate receptor. Adv Drug Deliv Rev 2004, 56:1111-1125.
4. Macdonald J.S., Gohmann J.J. Chemotherapy of advanced gastric cancer: present status, future prospects. Semin Oncol 1988, 15:42-49.
5. Rougier P., Van Cutsem E., Bajetta E., Niederle N., Possinger K., Labianca R., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407-1412.
6. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
7. Salonga D., Danenberg K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D.D., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000, 6:1322-1327.
8. Yau K., Price P., Pillai R.G., Aboagye E. Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors. Eur J Nucl Med Mol Imaging 2006, 33:981-987.
9. Perumal M., Pillai R.G., Barthel H., Leyton J., Latigo J.R., Forster M., et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res. 2006, 66:8558-8564.
10. Pressacco J., Mitrovski B., Erlichman C., Hedley D.W. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res 1995, 55:1505-1508.
11. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002, 29:1462-1469.
12. 11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst 2003, 95:675-682.
13. Pillai R.G., Forster M., Perumal M., Mitchell F., Leyton J., Aibgirhio F.I., et al. Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945. Cancer Res 2008, 68:3827-3834.
14. 18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. Clin Cancer Res 2009, 15:6649-6657.
15. 18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br J Cancer 2008, 99:481-487.
16. 18F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent. Eur J Nucl Med Mol Imaging 2007, 34:1406-1409.
17. Lee S.J., Yang E.K., Kim S.G. Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation. Mol Pharmacol 2006, 70:415-425.
18. Sherley J.L., Kelly T.J. Human cytosolic thymidine kinase. Purification and physical characterization of the enzyme from HeLa cells. J Biol Chem 1988, 263:375-382.
19. Mahteme H., Larsson B.S., Sundin A., Graf W. 5-FU uptake in liver metastases after intravenous and intraperitoneal administration: an autoradiographic study in the rat. Anticancer Res 1998, 18:943-949.
20. 18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice. J Nucl Med 2008, 49:2057-2066.
21. Choi S.J., Kim S.Y., Kim S.J., Lee J.S., Lee S.J., Park S.A., et al. Reproducibility of the kinetic analysis of 3′-deoxy-3′-[(18)F]fluorothymidine positron emission tomography in mouse tumor models. Nucl Med Biol 2009, 36:711-719.
22. Xiao Z., Xue J., Sowin T.J., Rosenberg S.H., Zhang H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 2005, 24:1403-1411.
23. Wong A., Soo R.A., Yong W.P., Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009, 41:77-88.
24. Hanauske A.R., Dittrich C., Otero J. Overview of phase I/II pemetrexed studies. Oncology 2004, 18:18-25.
25. Li L.J., Naeve G.S., Lee A.S. Temporal regulation of cyclin A-p107 and p33cdk2 complexes binding to a human thymidine kinase promoter element important for G1-S phase transcriptional regulation. Proc Natl Acad Sci USA 1993, 90:3554-3558.
26. Tommasi S., Pfeifer G.P. Constitutive protection of E2F recognition sequences in the human thymidine kinase promoter during cell cycle progression. J Biol Chem 1997, 272:30483-30490.
27. Kinsella A.R., Smith D., Pickard M. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 1997, 75:935-945.
28. Grem J.L., Fischer P.H. Enhancement of 5-fluorouracil's anticancer activity by dipyridamole. Pharmacol Ther 1989, 40:349-371.
29. Köhne C.H., Hiddemann W., Schüller J., Weiss J., Lohrmann H.P., Schmitz-Hübner U., et al. Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. J Clin Oncol 1995, 13:1201-1208.
30. Pizzorno G., Sun Z., Handschumacher R.E. Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil. Biochem Pharmacol 1995, 49:553-557.
31. Fraile R.J., Baker L.H., Buroker T.R., Horwitz J., Vaitkevicius V.K. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980, 40:2223-2228.
32. Yeh K.H., Yeh S.H., Hsu C.H., Wang T.M., Ma I.F., Cheng A.L. Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil. Br J Cancer 2000, 83:1510-1515.
33. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003, 63:3791-3798.
34. Welsh S.J., Titley J., Brunton L., Valenti M., Monaghan P., Jackman A.L., et al. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. Clin Cancer Res 2000, 6:2538-2546.
35. Lee J.H., Park J.H., Jung Y., Kim J.H., Jong H.S., Kim T.Y., et al. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther 2006, 5:3085-3095.